As biotech and pharma companies have become more streamlined and “virtual”, the use of CROs to conduct and/or manage portions of, or all of, a complete IND-enabling program has become common practice. However, the complexity of such programs, involving expertise in drug synthesis, regulatory, CMC, bioanalysis, toxicology, chemistry, pathology, and related disciplines makes management of these many inputs very challenging and subject to risks of poor execution or delayed submissions. This webinar, presented by a CRO-industry veteran, will provide insights on best practices, highlight common pitfalls, and identify “trade secrets” that can benefit industry newcomers, as well as more seasoned professionals. Topics addressed in this webinar include CRO qualification/selection, contracts, scheduling, protocol/program design, study conduct and monitoring, data and report review, and more. Here we discuss how to more effectively and constructively interact with CRO partners and ultimately save time, money & headaches in your development programs.
Register to gain access to gated resources.
Thank you for registering!
You may now view the resource below.
In this paper, we review appropriate definitions and describe the theoretical basis of why accurate mass approaches offer a significant advantage over nominal mass approaches in the arena of qualitative analysis and, specifically, metabolite identification.
Toxicology studies in drug development help identify potential safety issues and target organs in humans to identify translational markers of potential toxicity in later human trials and they can provide high-quality and reliable data on which to base the safe starting dose in humans. The data from these studies, and particularly the no-observed-adverse-effect level (NOAEL) information is essential for the safe and effective development of new drugs. In this podcast, we discuss the importance of NOAEL information in safety and toxicology studies.
In this podcast, we discuss 5 common errors in designing and managing IND-enabling toxicology programs with a special guest: Glenn Washer, EVP of Global Safety and Toxicology at Frontage Laboratories, Inc.